Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | CTSB | P07858 | 6/20 | 0.39 |
| ▸ | CTSS | P25774 | 6/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5630394 | 1.00 | L3MBTL1 (0.44) | L3MBTL1METAP2KAT6ACTSKCTSB | |
| SCHEMBL5631803 | 1.00 | L3MBTL1 (0.44) | L3MBTL1METAP2KAT6ACTSKCTSB | |
| SCHEMBL5631800 | 1.00 | L3MBTL1 (0.44) | L3MBTL1METAP2KAT6ACTSKCTSB | |
| SCHEMBL5632779 | 1.00 | L3MBTL1 (0.44) | L3MBTL1METAP2KAT6ACTSKCTSB | |
| SCHEMBL14384120 | 0.86 | CTSK (0.44) | L3MBTL1KAT6ACTSKCTSBCTSS | |
| SCHEMBL14384118 | 0.86 | CTSK (0.44) | L3MBTL1KAT6ACTSKCTSBCTSS | |
| SCHEMBL5632728 | 0.82 | L3MBTL1 (0.48) | L3MBTL1METAP2KAT6ACTSKCTSB | |
| SCHEMBL14384121 | 0.82 | L3MBTL1 (0.48) | L3MBTL1METAP2KAT6ACTSKCTSB | |
| SCHEMBL6611788 | 0.82 | L3MBTL1 (0.48) | L3MBTL1METAP2KAT6ACTSKCTSB | |
| SCHEMBL5631694 | 0.82 | L3MBTL1 (0.50) | L3MBTL1METAP2KAT6ACTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288541-B2 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | CTSK, CTSB, CTSS | L3MBTL1 1234/4885METAP2 509/4885KAT6A 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.